Product Description
CYCLIZINE (SYE kli zeen) is an antihistamine. It is used to prevent and to treat the nausea, vomiting, or dizziness of motion sickness. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. (Sourced from: https://my.clevelandclinic.org/health/drugs/19014-cyclizine-oral-tablets)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Canada | Denmark | Egypt | Finland | Germany | Greece | Ireland | Italy | Malta | New Zealand | Norway | Pakistan | Singapore | South Africa | Taiwan | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/13/2025 |
News Article |
GLOBAL PHILANTHROPIES COMMIT $300 MILLION TO ACCELERATE SOLUTIONS ON CLIMATE AND HEALTH |
|
11/10/2025 |
News Article |
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network |
|
11/06/2025 |
News Article |
Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell |
|
10/27/2025 |
News Article |
Elite Athletes Join Forces With Global Leaders to Launch Adapt2Win, a Bold Climate Adaptation Campaign Ahead of COP30 |